The New York Times is reporting that the first injectable H1N1 vaccines have shipped from vaccine maker Sanofi-Aventis. Previously, the first H1N1 vaccinations were to be the live virus type, in the form of a nasal spray. However, live virus vaccines are not recommended for certain groups including pregnant women, people with health problems, and adults over the age of 50 – some of the groups most at risk should they contract H1N1 infection. Sanofi-Aventis has a contract with the US government to provide 75 million doses of the vaccine, which will be provided free to physicians and health care workers. Health officials say there will eventually be enough vaccine for anyone who wants one, but priority will be given to high-risk groups first. The seasonal flu vaccine is currently distributed in sufficient quantity to the general public. Stay tuned to for up-to-date recommendations for the H1N1 vaccine as it becomes more widely available. [via Kaiser Health News]
Share your comments here.
Follow us on Twitter
Become a fan on Facebook
Dr. Steven Chang, the author of DailyDose, is a staff physician with Kosmix RightHealth. Dr. Chang practices Family Medicine at the University of California Davis Medical Center, where his medical interests include both pediatric and geriatric care, public health, gay and lesbian health, and sleep medicine. Dr. Chang trained at the Stanford University affiliated O'Connor Hospital, and was a research fellow at the National Institute of Health. He holds an M.D. from McGill University and a BA in Public Health from Johns Hopkins University.